John Poss, CEO, GB Sciences, accepted the award on behalf of GB Sciences, but then passed it on to Dr. Andrea Small-Howard and Dr. Helen Turner, recognizing that it is their scientific work that is deserving of the Award.
“We are grateful to be recognized for our work at the intersection of cannabis research and the treatment of debilitating diseases, including cancer, Alzheimer’s and Parkinson’s diseases,” said Mr. Poss. He continued. “Too often, sick people are denied treatments because of the prejudices against new and innovative medicines. Fortunately, in California, Nevada and an increasing number of states, patients have legal access to medical cannabis for the treatment of pain and side effects of other remedies, such as chemotherapy. In a country wracked by the opioid crisis, it is unconscionable that safe access is denied anywhere. At GB Sciences, we are taking medical cannabis to the next level, by uncovering the plant’s chemical compounds that can be used to prevent or cure illnesses when used in specific combinations. Our success depends on the support of communities like yours.”
About GB Sciences, Inc.
GB Sciences, Inc. (GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company’s goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note: Although the Company’s research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.
View original content with multimedia:http://www.prnewswire.com/news-releases/gb-sciences-receives-the-prestigious-spirit-of-the-law-award-300543654.html
SOURCE GB Sciences, Inc.
Powered by WPeMatico